Skip to main content
SpringerLink
Log in

Selective Inhibitors of Butyrylcholinesterase

A Valid Alternative for Therapy of Alzheimer’s Disease?

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The brain of mammals contains two major forms of cholinesterases (ChEs): acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The two forms differ genetically, structurally and in their kinetics. Butyrylcholine is not a physiological substrate in mammalian brains which makes the function of BuChE difficult to interpret. In human brains, BuChE is found in neurons and glial cells as well as in neuritic plaques and tangles in patients with Alzheimer’s disease (AD).While AChE activity decreases progressively in the brain of patients with AD, BuChE activity shows some increase.

In order to study the function of BuChE, we perfused intracortically the rat brain with a selective BuChE inhibitor. We found that extracellular acetylcholine levels increased 15-fold from 5 nmol/L to 75 nmol/L concentrations, with little cholinergic adverse effect in the animal. Based on these data, we postulated that two pools of ChEs may be present in the brain: one mainly neuronal and AChE dependent; and one mainly glial and BuChE dependent. The two pools show different kinetic properties with regard to regulation of acetylcholine concentration in the brain and can be separated with selective inhibitors.

The recent development of highly selective BuChE inhibitors will allow us to test these new agents in patients with AD in order to find out whether or not they represent an advantage for the treatment of patients with AD as compared with selective (donepezil) or relatively non-selective (rivastigmine, galantamine) ChE inhibitors presently in use.

The association between a BuChE-K variant and AD has not been confirmed in several studies.

In conclusion, additional experimental and clinical work is necessary in order to elucidate the role of BuChE in normal brain function and in the brains of patients with AD. In the future, it may be possible that selective BuChE inhibitors will have a role in treatment of patients with advanced AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Silver A. The biology of cholinesterases. Amsterdam: Elsevier, 1974: 426–47

    Google Scholar 

  2. Giacobini E, Holmstedt B. Cholinesterase content of certain regions of the spinal cord as judged by histochemical and cartesian diver technique. Acta Physiol Scand 1958; 42: 12–27

    Article  PubMed  CAS  Google Scholar 

  3. Giacobini E. Distribution and localization of cholinesterases in nerve cells. Acta Physiol Scand 1959; 45 Suppl. 156: 1

    CAS  Google Scholar 

  4. Giacobini E. Metabolic relations between glia and neurons studied in single cells. In: Maynard M, Cohen MD, Snider R, editors. Morphological and biochemical correlates of neural activity. New York: Harper & Row, 1964: 15–38

    Google Scholar 

  5. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles and patterns of selective vulnerability. Ann Neurol 1993; 34: 373–84

    Article  PubMed  CAS  Google Scholar 

  6. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273–7

    Article  PubMed  CAS  Google Scholar 

  7. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development — a study of molecular forms. Neurochem Int 1992; 21(3): 381–96

    Article  PubMed  CAS  Google Scholar 

  8. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979; 171: 319–27

    Article  PubMed  CAS  Google Scholar 

  9. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J Neurochem 1987; 48(6): 1687–92

    Article  PubMed  CAS  Google Scholar 

  10. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986; 47(1): 263–77

    Article  PubMed  CAS  Google Scholar 

  11. Arendt T, Bruckner M, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development — a study of molecular forms. J Neurochem 1992; 21(3): 231–44

    Google Scholar 

  12. Giacobini E, DeSarno P, Clark B, et al. The cholinergic receptor system of the human brain — neurochemical and pharmacological aspects in aging and Alzheimer. In: Nordberg A, Fuxe K, Holmstedt B, editors. Progress in brain research. Amsterdam: Elsevier, 1989: 335–43

    Google Scholar 

  13. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000: 181–226

    Google Scholar 

  14. Sussman JL, Harel M, Farlow F, et al. Atomic structure of acetylcholinesterase from Torpedo Californica: a prototypic binding protein. Science 1991; 253(5002): 872–9

    Article  PubMed  CAS  Google Scholar 

  15. Vellom DC, Radie Z, Li Y, et al. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry 1993; 32(1): 12–7

    Article  PubMed  CAS  Google Scholar 

  16. Shafferman A, Velan B, Ordentlich A, et al. Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center. EMBO J 1992; 11(10): 3561–8

    PubMed  CAS  Google Scholar 

  17. Iyo M, Namba H, Fukushi K, et al., Measurement of acetylcho linesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer’s disease. Lancet 1997; 349: 1805–9

    Article  PubMed  CAS  Google Scholar 

  18. Perry EK, Tomlison BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; II: 1457–9

    Article  Google Scholar 

  19. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994; 36(5): 722–7

    Article  PubMed  CAS  Google Scholar 

  20. Inestrosa NC, Alvarez A, Godoy J, et al. Acetylcholinesteraseamyloid-beta-peptide interaction and Wnt signaling involvement in neurotoxicity. Acta Neurol Scand 2000; 102: 1–7

    Article  Google Scholar 

  21. Ogane N, Giacobini E, Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 1992; 17(5): 489–95

    Article  PubMed  CAS  Google Scholar 

  22. Ogane N, Giacobini E, Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res 1992; 17(5): 307–12

    Article  Google Scholar 

  23. Giacobini E, Griffini PL, Maggi T, et al. The effect of MF8622, a selective butyrylcholinesterase inhibitor on cortical levels of acetylcholine [abstract]. Society for Neuroscience Annual Meeting; 1995 Nov 11–16; San Diego (CA)

  24. Cuadra G, Summers K, Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortes in vivo. J Pharmacol Exp Ther 1994; 270(1): 277–84

    PubMed  CAS  Google Scholar 

  25. Cuadra G, Giacobini E. Coadministration of Cholinesterase inhibitors and idazoxan: effects of neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 1995; 273: 230–40

    PubMed  CAS  Google Scholar 

  26. Massoulié J, Toutant JP. Vertebrates ChEs: structure and types of interaction. Chapter 86. In: Whittaker VP, editor. Handbook of experimental pharmacology. Berlin-Heidelberg: Springer Verlag, 1988: 167–224

    Google Scholar 

  27. Yu Q, Holloway HW, Utsuki T, et al. Synthesis of novel phenser-ine-based selective inhibitors of butyrylcholinesterase for Alzheimer’s disease. J Med Chem 1999; 42(10): 1855–61

    Article  PubMed  CAS  Google Scholar 

  28. Greig NH, Utsuki T, Yu Q, et al. Butyrylcholinesterase: a new therapeutic target in Alzheimer’s disease treatment? Alz Insights 2001; 7(2): 1–4

    Google Scholar 

  29. Yu GS, Holloway HW, Flippen-Anderson F, et al. Methyl analogues of the experimental Alzheimer’s drug phenserine: synthesis and structure-activity relationship for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem 2001; 38: 198–221

    CAS  Google Scholar 

  30. Lahiri DK, Farlow MR, Hintz N, et al. Cholinesterase inhibitors, beta amyloid precursor protein and amyloid beta-pep-tides in Alzheimer’s disease. Acta Neurol Scand 2000; 102: 60–7

    Article  Google Scholar 

  31. Shaw KTY, Utsuki T, Rogers J, et al. Phenserine regulates translation of B-amyloid precursor protein mRNA by a putative interleukin-1 responsive element: a target for drug development. Proc Nat Acad Sci USA 2001; 98: 7605–10

    Article  PubMed  CAS  Google Scholar 

  32. Haroutunian V, Ahlers SA, Greig NH, et al. Induction, secretion and pharmacological regulation of beta-APP in animal model systems. In: Fisher A, Yoshida M, Hanin I, editors. Progress in Alzheimer’s and Parkinson’s disease. New York: Plenum, 1997

    Google Scholar 

  33. Costa J, Anand R, Cutler N, et al. Correlation between cognitive effects and level of acetylcholinesterase inhibition in a trial of rivastigmine in Alzheimer’s patients [poster NR 561]. American Society of Psychiatry Annual Meeting; 1999; Chicago (IL)

  34. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E 4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet 1997; 6(11): 1933–6

    Article  PubMed  CAS  Google Scholar 

  35. Tilley L, Morgan K, Grainger J, et al. Evaluation of polymorphism in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer’s disease. Eur J Hum Genet 1999; 7(6): 659–63

    Article  PubMed  CAS  Google Scholar 

  36. Meilroy SP, Crawford VLS, Dynan KB, et al. Butyrylcholinesterase k variant is genetically associated with late onset Alzheimer’s disease in Northern Ireland. J Med Genet 2000; 37(3): 182–5

    Article  Google Scholar 

  37. Panegyres PK, Mamotte CDS, Vasikaran SD, et al. Butyrylcholinesterase K variant and Alzheimer’s disease. J Neurol 1999; 246(5): 369–70

    Article  PubMed  CAS  Google Scholar 

  38. Singleton AB, Gibson AM, Edwarson JA. Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet 1998; 351: 1818

    Article  PubMed  CAS  Google Scholar 

  39. Kehoe PG, Williams H, Holmans P, et al. The butyrylcholinesterase K variant and susceptibility to Alzheimer’s disease. J Med Genet 1998; 35(12): 17201

    Article  Google Scholar 

  40. Russ C, Powell J, Lovestone S, et al. K variant of butyrylcholinesterase and late-onset Alzheimer’s disease. Lancet 1998; 351:881

    Article  PubMed  CAS  Google Scholar 

  41. Yamamoto Y, Yasuda M, Mori E, et al. Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon 4 allele of the apolipoprotein gene in Japanese patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1999; 67(1): 94–6

    Article  PubMed  CAS  Google Scholar 

  42. Grubber JM, Saunders AM, Cranegatherum AR, et al. Analysis of association between Alzheimer’s disease and the K variant of butyrylcholinesterase. Neurosci Lett 1999; 269(2): 115–9

    Article  PubMed  CAS  Google Scholar 

  43. Lee DW, Liu HC, Chi C, et al. No association between butyrylcholinesterase K-variant and Alzheimer’s disease in Chinese. Am J Med Genet 2000; 96(2): 167–9

    Article  PubMed  CAS  Google Scholar 

  44. Yamamoto Y, Sengo M, Yasuda M, et al. No association between Presinilin 1 Intron gene or Butyrylcholinesterase K variant and Alzheimer’s disease in Japanese populations. Psychogeriatrics 2001; 1(1): 108–18

    Article  Google Scholar 

  45. Yamada M, Sodeyama N, Itoh Y, et al. Butyrylcholinesterase K variant and cerebral amyloid angiopathy. Stroke 1998; 29(12): 2488–90

    Article  PubMed  CAS  Google Scholar 

  46. Greig NH, Utsuki T, Yu QS, et al. A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17(3): 1–7

    Google Scholar 

  47. Ballard, CG. Advances in the treatment of Alzheimer’s disease: benefits of dual Cholinesterase inhibition. Eur Neurol 2001; 46(4): 136–42

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used in preparation of this manuscript. The author has no conflicts of interest directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Department of Geriatrics, School of Medicine, University Hospitals of Geriatrics, University of Geneva, Geneva, Switzerland

    Ezio Giacobini

Authors
  1. Ezio Giacobini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ezio Giacobini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giacobini, E. Selective Inhibitors of Butyrylcholinesterase. Drugs Aging 18, 891–898 (2001). https://doi.org/10.2165/00002512-200118120-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118120-00001

Keywords

Search

Navigation